Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
15.02. | New survival data for Merck, Eisai's Keytruda/Lenvima combo shows promise in kidney cancer | ||
15.02. | Pfizer's basic instincts | ||
12.02. | STEM founder Rob Wood secures a 25% stake in performance-io | ||
12.02. | EMA begins rolling review of CureVac's COVID-19 vaccine | ||
12.02. | Sandoz to acquire GSK's cephalosporin antibiotic brands for up to $500m | ||
12.02. | Roche's anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients | ||
12.02. | Virgo Health appoints Sarah Gordon as head of health | ||
11.02. | NICE turns down bluebird bio's gene therapy Zynteglo | ||
11.02. | Q&A: Emily Spilko | ||
11.02. | WHO backs AZ/Oxford COVID-19 vaccine, including in older adults | ||
11.02. | AZ forecasts growth in 2021 after revenues surge in Q4 | ||
11.02. | AZ partners with IDT Biologika to bolster manufacturing for COVID-19 vaccine in EU | ||
11.02. | Diana Evans joins Makara Health's leadership team as director | ||
11.02. | A Community of Purpose | ||
10.02. | ICER extends evaluation of Biogen's aducanumab after FDA delay | ||
10.02. | Communiqué Awards 2021 are open for entry! | ||
10.02. | FDA grants emergency use for Lilly's COVID-19 antibody drug combination | ||
10.02. | NIH trial of AZ's long-acting COVID-19 antibody launches in the US | ||
10.02. | Verily and Janssen to collaborate on home-based COVID-19 immune response study | ||
10.02. | The remote working revolution | ||
10.02. | Eli Lilly promotes Anat Ashkenazi to chief financial officer | ||
09.02. | FDA considers new safety warnings for Pfizer's JAK inhibitor Xeljanz | ||
09.02. | EU orders another 300 million doses of Pfizer/BioNTech's COVID-19 vaccine | ||
09.02. | BMS and Exelixis' Opdivo/Cabometyx shows continued benefit in kidney cancer | ||
09.02. | Janssen's Erleada improves survival in certain advanced prostate cancer patients |